成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

Seragon Pharmaceuticals  
Seragon Pharmaceuticals 前身是Aragon的乳癌藥物開發部門

Seragon Pharmaceuticals’ orally active selective estrogen receptor degraders (SERDs) represent a potential new treatment for progressive metastatic breast cancer that may circumvent the problem of resistance to anti-hormonal therapies. SERDs are estrogen receptor antagonists that also induce a conformational change that results in the degradation of the receptor. Seragon has identified multiple SERDs that have pharmacokinetic profiles sufficient to drive a robust therapeutic response and result in degradation of the receptor and anti-tumor activity. The novel profile of these potent, orally bioavailable, nonsteroidal agents may result in greater efficacy and response rates in patients with hormone-refractory breast cancer compared to other drugs in development. Seragon’s most advanced leads induce tumor regressions in both tamoxifen sensitive and tamoxifen resistant tumor models in vivo. Based on these results and others, the company is currently advancing multiple, distinct lead SERD chemical scaffolds toward clinical development. Seragon’s SERDs are initially being developed for the treatment of women with late-stage, progressive metastatic disease.